DEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Novo Nordisk A/S following a class action lawsuit filed on behalf of investors who acquired Novo securities during the specified class period from May 7, 2025, to July 28, 2025 [1][3] Summary by Sections Lawsuit Details - The lawsuit alleges that Novo Nordisk made false and misleading statements regarding the impact of compounded GLP-1 drugs, specifically underestimating the effect of the FDA's personalization exception that allows many patients to continue using compounded alternatives [3] - It is claimed that Novo overstated the likelihood of patients switching to its branded drugs, such as Ozempic® and Wegovy®, leading to significant investor losses [3] Investor Information - Investors who purchased Novo securities during the class period have until September 30, 2025, to seek appointment as a lead plaintiff representative of the class [2] Company Background - Novo Nordisk is a global pharmaceutical company headquartered in Denmark [2]